Lichen China
LICN
2 hedge funds and large institutions have $19K invested in Lichen China in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0.65% less ownership
Funds ownership: 1.31% → 0.66% (-0.65%)
46% less capital invested
Capital invested by funds: $35.1K → $19K (-$16.1K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$12.1K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $19K | -$12.1K | -2,705 | -38% |
|
|
2
Acadian Asset Management
Boston,
Massachusetts
| – | -$7.15K | -1,594 | -100% |
|
LICN Hedge Fund Activity: Q3 2025 in Review
2 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Lichen China (LICN) for Q3 2025, worth a combined $19K — down 46% from $35.1K a quarter earlier.
Fund positioning in LICN was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was UBS Group, cutting an estimated $12.1K.
- 2 institutional investors held Lichen China (LICN) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $19K of Lichen China stock for Q3 2025, down 46% quarter-over-quarter.
- 0 funds opened new Lichen China positions in Q3 2025 and 0 closed out.
- The largest Lichen China seller in Q3 2025 was UBS Group, an estimated $12.1K sold.
Based on aggregated 13F filings for Q3 2025.